Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.
- DOI
- 10.1200/jco-25-01929
- Published
- 2026 Apr
- Container
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1200/jco-25-01929,
title = {Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.},
author = {Zhou H and Zhao H and Hou X and Wang Y and He Z and Li Y and Ma Y and Zhao Y and Huang Y and Chen L and Xiao S and Zhu H and Zhu Y and Fang W and Zhang L and Yang Y},
year = {2026},
journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
doi = {10.1200/jco-25-01929},
url = {https://doi.org/10.1200/jco-25-01929}
}RIS
TY - JOUR TI - Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study. AU - Zhou H AU - Zhao H AU - Hou X AU - Wang Y AU - He Z AU - Li Y AU - Ma Y AU - Zhao Y AU - Huang Y AU - Chen L AU - Xiao S AU - Zhu H AU - Zhu Y AU - Fang W AU - Zhang L AU - Yang Y PY - 2026 JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology DO - 10.1200/jco-25-01929 UR - https://doi.org/10.1200/jco-25-01929 ER -
APA
H, Z., H, Z., X, H., Y, W., Z, H., Y, L., Y, M., Y, Z., Y, H., L, C., S, X., H, Z., Y, Z., W, F., L, Z., & Y, Y. (2026). Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-25-01929
Source records
- pubmed · retrieved 2026-09-27T09:54:39.582Z